#NotImmune - Alliance for Cancer Gene Therapy Alliance for Cancer Gene Therapy funds research to: Attack the cancer, not the patient. http://www.acgtfoundation.org/notimmune ACGT is the nation's only nonprofit dedicated exclusively to funding... By: ACGTFoundation … Continue reading →

A gene therapy spinout from Childrens Hospital of Philadelphia has added a head of regulatory affairs as it continues Phase 3 clinical trials for its treatment to reverse the effects of inherited retinal degeneration caused by a mutation in the RPE65 gene. It is the latest in a series of additions to the company following a $72.8 million Series B fundraise earlier this year. Daniel Takefman previously worked for eight years as chief of the gene therapy branch at the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration, according to a company statement. Spark Therapeutics, headed by CEO Jeffrey Marrazzo, has been bulking up its management muscle this year. Dr. Katherine High, the former founding director of the Center for Cellular and Molecular Therapeutics at CHOP and a pediatrician at the Perelman School of Medicine, became president and Chief Scientific Officer and has a board seat. It added Stephen Webster as CFO from Optimer Pharmaceuticals and Adolor Corp, whic Cubist Pharmaceuticals acquired in 2011. Steven Gelone joined as head of clinical research and development. Gelone had previously worked for ViroPharma in a similar role Shire acquired the company last year. Diane Blumenthal, another industry veteran, … Continue reading →